Driehaus Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Driehaus Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.5M	Sell	2,987,147 -122,356	-4%	-$1.72M	0.31%	114
2025 Q4	$37.6M	Buy	3,109,503 +688,736	+28%	+$9.35M	0.26%	130
2025 Q3	$32.9M	Buy	2,420,767 +1,155,770	+91%	+$10.9M	0.24%	141
2025 Q2	$8.11M	Buy	+1,264,997	New	+$6.15M	0.06%	272

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Driehaus Capital Management's AMLX Position: Q1 2026 in Review

Driehaus Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 3.9% in Q1 2026, selling an estimated $1.72M and leaving 2,987,147 shares worth $41.5M. The position accounts for 0.31% of the portfolio, ranked #114.

Driehaus Capital Management first reported a position in AMLX in Q2 2025 and has held it in 4 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Driehaus Capital Management held 2,987,147 shares of Amylyx Pharmaceuticals worth $41.5M as of Q1 2026.
Driehaus Capital Management sold 122,356 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
Amylyx Pharmaceuticals made up 0.31% of Driehaus Capital Management's portfolio in Q1 2026, its #114 holding.
Driehaus Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.